AstraZeneca recently announced that the FDA granted accelerated approval to camizestrant (Etcamah) in combination with a CDK4/6 inhibitor for adults with HR-positive/HER2-negative locally advanced or metastatic breast cancer. The indication applies when an ESR1 mutation is detected during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy using an FDA-authorized test. Approval Highlights SERENA-6 reduced the risk […]
Eli Lilly announced on August 31 that it has entered into a definitive agreement to acquire Merida Biosciences, a U.S. biotech developing therapies for serious autoimmune and allergic diseases, for up to $2.875 billion in cash. The total includes an upfront payment and contingent milestone payments, with closing expected in Q4 2026. Merida is developing […]
Johnson & Johnson announced on August 24 that the FDA approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older previously or currently treated with corticosteroids. It is the first FDA-approved treatment for wAIHA. The approval adds the first treatment option for this rare blood disorder and marks the expansion […]
Moderna and Merck have announced five-year follow-up data from the Phase 2b KEYNOTE-942 study of intismeran autogene (mRNA-4157/V940), an individualized mRNA neoantigen therapy, in combination with Keytruda (pembrolizumab) for patients with high-risk melanoma. The data highlight the potential of personalized mRNA approaches in precision oncology. Key Points Next-gen cancer immunotherapy enabled by personalized mRNA technology […]
Jazz Pharmaceuticals has announced that it will acquire U.S.-based Actio Biosciences in a deal valued at up to $1.32 billion. The transaction is notable for the up to $1.32 billion value placed on an early-clinical rare epilepsy program built around a genetics-driven precision-medicine approach. Key Points Deal valued at up to $1.32B ABS-1230 in Phase […]
AstraZeneca has signed a licensing agreement with Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical, for ex-China rights to TQC3721, a chronic obstructive pulmonary disease candidate. The deal is drawing attention as another sign that China-origin clinical assets are becoming part of global pharma pipeline strategy beyond oncology, metabolic, and kidney disease. Deal Highlights $200M […]
Novartis has announced that it will acquire U.K.-based biotech company Myricx Bio. The transaction is drawing attention as another signal that, in ADCs, differentiation is increasingly moving beyond tumor target selection and toward payload innovation. Deal Highlights $1.1B upfront; total potential value of up to $1.5B Next-generation ADC platform using N-myristoyltransferase inhibitor (NMTi) payload technology […]
Ipsen has announced that it will acquire U.S.-based Kartos Therapeutics. The transaction includes an upfront payment of $450 million and up to $1.3 billion in development, regulatory, and sales milestones, bringing the total potential value to up to $1.75 billion. Deal Highlights $450M upfront; total potential value of up to $1.75B Navtemadlin: late-stage MDM2 inhibitor […]
AbbVie has announced that it will acquire Apogee Therapeutics, a biotech company focused on immunology and inflammatory diseases, in a cash transaction valued at approximately $10.9 billion. Through the acquisition, AbbVie will gain Apogee’s long-acting antibody pipeline, led by zumilokibart. Deal Highlights Transaction value of approximately $10.9 billion Purchase price of $135.11 per share Lead […]
GSK has announced that it will acquire oncology biotech Nuvalent in a $10.6 billion cash transaction. Nuvalent is developing targeted therapies for non-small cell lung cancer, including its lead candidates zidesamtinib and neladalkib, which are currently under FDA review. Deal Overview $10.6 billion cash transaction Purchase price of $124 per share Lead candidates include zidesamtinib […]